AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Tamoxifen use by breast cancer patients increases the risk that aggressive contralateral tumors will develop, a small retrospective study suggests.
Dr. Christopher I. Li and his colleagues at[the Fred Hutchinson Cancer Research Center in Seattle compared 89 tamoxifen users with 100 nonusers of tamoxifen, aged 50 years and older and diagnosed with primary unilateral invasive breast cancer. The. study subjects were identified through a population-based tumor registry of 8,981 women.
Those who used tamoxifen had a 10% decreased overall risk of contralateral tumor recurrence and a 20% decreased risk Of developing less aggressive estrogen receptor (ER)-positive tumors but were 4.9 times more likely to develop the more aggressive ER-negative tumors, for which there is no medical treatment.
The differences in risk based on ER status were statistically significant, the investigators reported (J. Natl. Cancer Inst. 93[13]:1008-13, ...
Source: HighBeam Research, Tamoxifen Tied to Aggressive Contralateral Disease.